Bispecifics: The Next Frontier in Cancer Immunotherapy

BioNTech and Pfizer just dropped promising bispecific antibody data at ASCO 2026, and the FDA's top oncologist is taking notes. These engineered molecules could redefine how we treat hard-to-beat cancers.

The Science

Bispecific antibodies are artificial proteins designed to grab two different targets at once. In this case, one arm latches onto a cancer cell while the other hooks a T cell, forcing the immune system to attack the tumor. This dual-targeting strategy aims to overcome the limitations of traditional monoclonal antibodies, which only recognize one antigen.

The phase 1 and 2 trials presented at ASCO showed objective response rates above 30% in certain B-cell lymphomas, with complete remissions in nearly one-fifth of patients. Importantly, side effects were manageable—mostly low-grade cytokine release syndrome (CRS), a known immune activation response. Dr. Richard Pazdur, FDA's oncology chief, called the data "encouraging" and hinted at accelerated review pathways.

“Bispecifics could become the third pillar of immunotherapy, alongside checkpoint inhibitors and CAR-T cells.”

Key Findings

• Response rate: In the BioNTech trial, 34% of patients with diffuse large B-cell lymphoma responded, including 18% complete responses.
• Durability: Median duration of response exceeded 12 months among responders, a meaningful outcome for aggressive cancers.
• Safety profile: 65% of patients experienced grade 1-2 CRS; no treatment-related deaths occurred.
• Dosing: Administered intravenously every 2-3 weeks, making them feasible for outpatient settings.

Why It Matters

For patients with hematologic cancers who have exhausted chemotherapy and targeted therapies, bispecifics offer a potent off-the-shelf alternative. Unlike CAR-T cells, which require weeks of personalized manufacturing, bispecifics are ready to infuse, cutting wait times dramatically.

The mechanism is elegant: by physically bridging a T cell to a cancer cell, the bispecific creates an immune synapse that triggers tumor killing. This bypasses the need for the immune system to recognize the tumor on its own—a common failure point in immunosuppressive microenvironments.

Pazdur's optimism signals that the FDA may move quickly on approvals, potentially opening the door to combinations with checkpoint inhibitors or cancer vaccines.

Your Protocol

While these treatments are still experimental, patients and caregivers can take proactive steps:

1. 1Explore clinical trials: Search clinicaltrials.gov for bispecific antibody studies matching your cancer type. Major cancer centers are actively recruiting.
2. 2Talk to your oncologist: Ask whether you might qualify for a bispecific trial, especially if you've had multiple prior treatments.
3. 3Track side effects: CRS can cause fever and fatigue. Keep a symptom diary to share with your care team.
4. 4Support your immune system: Prioritize anti-inflammatory nutrition, quality sleep, and stress management—a robust immune system may enhance immunotherapy response.

What To Watch Next

The coming months will be pivotal. Phase 3 trials comparing bispecifics to standard of care in B-cell lymphoma are expected to report soon. Competitors like Regeneron and Amgen have similar candidates in the pipeline.

A key question is whether bispecifics can work in solid tumors, where immunotherapy has struggled. Early studies in lung and breast cancer are underway, though initial results are mixed.

The Bottom Line

Bispecific antibodies are a concrete advance in cancer care. With solid efficacy data and a manageable safety profile, they are poised to change treatment paradigms. For patients, this means new hope; for science, a smarter way to harness the immune system. The next few years will determine just how far this technology can go.

Expanded Context: The Immunotherapy Landscape

To appreciate the impact of bispecifics, it's helpful to place them within the broader immunotherapy landscape. Checkpoint inhibitors (like pembrolizumab) revolutionized treatment by "releasing the brakes" on the immune system, but they only work in tumors with certain features, such as high mutational burden. CAR-T therapies, on the other hand, reprogram a patient's T cells to recognize cancer, but they are costly, require weeks of manufacturing, and are largely limited to hematologic malignancies. Bispecifics offer a middle ground: off-the-shelf products with direct mechanisms of action and potential applicability to both blood cancers and, eventually, solid tumors.

Emerging research suggests bispecifics could be combined with other modalities. For example, a 2025 preclinical study showed that adding a bispecific to a PD-1 inhibitor improved T-cell infiltration in triple-negative breast cancer tumors. Additionally, bispecifics targeting two tumor antigens (rather than one tumor antigen and a T-cell receptor) are in development, which could reduce toxicity and increase specificity. Regeneron has an anti-CD20xCD3 bispecific in phase 3 for follicular lymphoma, with interim results showing a 67% overall response rate.

Implications for Patients and Healthcare Systems

The arrival of bispecifics has implications beyond clinical efficacy. From a public health perspective, these drugs could reduce the economic burden of personalized treatments. While a CAR-T therapy can cost over $400,000, bispecifics, being mass-produced, could be significantly cheaper, though official pricing has not been announced. Additionally, intravenous administration every 2-3 weeks simplifies hospital logistics and allows more patients to access treatment at community centers, not just large academic hubs.

For patients, the main advantage is immediacy. A patient with aggressive lymphoma who has relapsed after multiple lines of treatment can receive a bispecific within days, while waiting for CAR-T could take weeks, during which the disease may progress. This difference could translate into better outcomes, especially in fast-growing cancers.

Challenges and Ethical Considerations

Despite the optimism, challenges remain. Cytokine release syndrome (CRS) is still a concern, though in current trials it has been mostly low-grade. However, when severe CRS occurs, it requires management with tocilizumab and corticosteroids, adding complexity to treatment. There is also a risk of neurotoxicity, though less frequent than with CAR-T. Another challenge is resistance: some tumors may lose expression of the target antigen, becoming invisible to the bispecific. Researchers are developing bispecifics targeting multiple antigens to mitigate this.

From an ethical perspective, the question arises of how to prioritize access if these treatments prove superior. Since current trials focus on patients with advanced cancers who have exhausted other options, expanding their use to earlier stages may be difficult without long-term survival data. Moreover, the FDA may face pressure to approve these drugs based on phase 2 data, which always carries uncertainty about long-term benefits.

Emerging Research: Beyond Lymphomas

While the strongest data come from hematologic cancers, research in solid tumors is advancing. A phase 1/2 trial of an anti-PSMAxCD3 bispecific in metastatic castration-resistant prostate cancer showed a disease control rate of 45% at 6 months, with partial responses in 12% of patients. In non-small cell lung cancer, an anti-EGFRxCD3 bispecific combined with a PD-L1 inhibitor achieved a 28% response rate in patients with PD-L1 expression <50%, a group that typically responds poorly to immunotherapy alone.

These results, though preliminary, suggest bispecifics may overcome some barriers in solid tumors, such as the immunosuppressive microenvironment and antigen heterogeneity. However, toxicity in solid tumors appears higher, possibly due to target antigen expression on normal tissues. For instance, the anti-EGFR bispecific caused skin rash and diarrhea in most patients—manageable side effects but requiring monitoring.

FDA Perspectives and Regulatory Pathway

Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence, has historically been cautious with accelerated approvals, but his comments at ASCO 2026 suggest a shift in tone. "These data are encouraging, and we are prepared to work with sponsors on accelerated review pathways if results hold in larger cohorts," he stated. This could mean the FDA will accept approval applications based on phase 2 data with surrogate endpoints like response rate, provided confirmatory studies are conducted later.

For BioNTech and Pfizer, this represents an opportunity to establish leadership in the bispecific space. Both companies have a long-standing collaboration on mRNA vaccines but are now diversifying into oncology therapies. If phase 3 data are positive, we could see the first approval of a bispecific for diffuse large B-cell lymphoma in 2027, changing the standard of care for this disease.

Your Detailed Protocol

While these treatments are still experimental, patients and caregivers can take concrete steps to prepare:

1. 1Explore clinical trials: Search clinicaltrials.gov for bispecific antibody studies matching your cancer type. Major cancer centers are actively recruiting. Pay attention to inclusion criteria, such as number of prior treatment lines and performance status.
2. 2Talk to your oncologist: Ask whether you might qualify for a bispecific trial, especially if you've had multiple prior treatments. Bring a list of questions: what are the risks of CRS? How are side effects managed? Are there associated costs?
3. 3Track side effects: CRS can cause fever, fatigue, muscle aches, and in rare cases, hypotension. Keep a daily symptom diary to share with your care team. If you're in a trial, the team will give specific instructions.
4. 4Support your immune system: Prioritize anti-inflammatory nutrition rich in fruits, vegetables, healthy fats, and lean proteins. Aim for 7-9 hours of quality sleep, and manage stress with techniques like meditation or yoga. A robust immune system may enhance immunotherapy response, though direct evidence is still limited.
5. 5Connect with support groups: Organizations like the Leukemia & Lymphoma Society offer resources and connections with other patients who have participated in bispecific trials. Sharing experiences can help you make informed decisions.

Conclusion: A New Chapter in the Fight Against Cancer

Bispecific antibodies are a concrete advance in cancer care. With solid efficacy data and a manageable safety profile, they are poised to change treatment paradigms. For patients, this means new hope; for science, a smarter way to harness the immune system. The next few years will determine just how far this technology can go, but for now, the horizon looks brighter.